# Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion

> **NCT04271332** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Clinical Research Associates, LLC** · enrollment: 60 (estimated)

## Conditions studied

- 16P11.2 Deletion Syndrome

## Interventions

- **DRUG:** Arbaclofen
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04271332
- **Lead sponsor:** Clinical Research Associates, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-01
- **Primary completion:** 2024-12-22
- **Final completion:** 2025-03-23
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04271332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04271332, "Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04271332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*